Browse LAIR1

Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF13895 Immunoglobulin domain
Function

Functions as an inhibitory receptor that plays a constitutive negative regulatory role on cytolytic function of natural killer (NK) cells, B-cells and T-cells. Activation by Tyr phosphorylation results in recruitment and activation of the phosphatases PTPN6 and PTPN11. It also reduces the increase of intracellular calcium evoked by B-cell receptor ligation. May also play its inhibitory role independently of SH2-containing phosphatases. Modulates cytokine production in CD4+ T-cells, down-regulating IL2 and IFNG production while inducing secretion of transforming growth factor beta. Down-regulates also IgG and IgE production in B-cells as well as IL8, IL10 and TNF secretion. Inhibits proliferation and induces apoptosis in myeloid leukemia cell lines as well as prevents nuclear translocation of NF-kappa-B p65 subunit/RELA and phosphorylation of I-kappa-B alpha/CHUK in these cells. Inhibits the differentiation of peripheral blood precursors towards dendritic cells.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LAIR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LAIR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.52 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LAIR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.330.358
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2080.901
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.420.74
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2410.578
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0860.952
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6630.737
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2680.601
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5380.713
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0670.968
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1090.516
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4490.589
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1610.37
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LAIR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LAIR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LAIR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LAIR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LAIR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LAIR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LAIR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLAIR1
Nameleukocyte-associated immunoglobulin-like receptor 1
Aliases CD305; leukocyte-associated Ig-like receptor 1; LAIR-1; CD antigen CD305; hLAIR1
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LAIR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.